<code id='4B20CAA696'></code><style id='4B20CAA696'></style>
    • <acronym id='4B20CAA696'></acronym>
      <center id='4B20CAA696'><center id='4B20CAA696'><tfoot id='4B20CAA696'></tfoot></center><abbr id='4B20CAA696'><dir id='4B20CAA696'><tfoot id='4B20CAA696'></tfoot><noframes id='4B20CAA696'>

    • <optgroup id='4B20CAA696'><strike id='4B20CAA696'><sup id='4B20CAA696'></sup></strike><code id='4B20CAA696'></code></optgroup>
        1. <b id='4B20CAA696'><label id='4B20CAA696'><select id='4B20CAA696'><dt id='4B20CAA696'><span id='4B20CAA696'></span></dt></select></label></b><u id='4B20CAA696'></u>
          <i id='4B20CAA696'><strike id='4B20CAA696'><tt id='4B20CAA696'><pre id='4B20CAA696'></pre></tt></strike></i>

          entertainment

          entertainment

          author:knowledge    Page View:424
          Matts Take Column Illustration
          Molly Ferguson for STAT

          If you’re a drug company executive, you probably feel like you got up on the wrong side of bed.

          On Thursday night, President Biden proposed expanding one of his most popular policies: the Medicare price negotiation process that was put in place as part of the Inflation Reduction Act. “Americans pay more for prescription drugs than anywhere else,” Biden said. “It’s wrong and I’m ending it.”

          advertisement

          Obviously, the drug industry is not going to be happy about new price limitations in the U.S., the biggest market for pharmaceuticals. But, even more than that, Biden’s move emphasizes a painful reality: That pharmaceutical companies remain one of the biggest political targets in the country — despite their key role in addressing the Covid-19 pandemic and their development of wildly effective new weight loss drugs.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more
          BioAge raises $170M for combination therapy with Zepbound
          BioAge raises $170M for combination therapy with Zepbound

          Illustration:STAT;Source:EliLilly/APACaliforniabiotechdevelopingacombinationtherapywiththeobesitydru

          read more
          How one medical school became remarkably diverse
          How one medical school became remarkably diverse

          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

          read more

          What we’ve learned from the Aduhelm mess

          MollyFergusonforSTATSTATnowpublishesselectedLetterstotheEditorreceivedinresponsetoFirstOpinionessays